Anderson Silva failed his post-UFC 183 drug screening for the banned substance drostanolone metabolites in addition to two benzodiazepine class drugs: Oxazepam and Temazepam.
The results were included in an official complaint filed against Silva by the Nevada Athletic Commission. Bleacher Report obtained a copy of the full complaint prior to Tuesday’s athletic commission meeting at the Grant Sawyer Building near downtown Las Vegas.
Oxazepam is typically used for treating withdrawal from alcohol, while Temazepam is used for treating insomnia. The complaint against Silva notes they are banned substances.
“The Positive/Anbormal Report for Benzodiazepines regarding the Post-Fight Quest Urinalysis indicates that Silva administered or used one or more prohibited Benzodiazepines before the contest.”
Silva was tested following his January 31 fight. His sample tested by the Sports Medicine Research and Testing Laboratory in Salt Lake City returned the presence of drostanolone metabolites. The commission received those results on February 10.
Another Silva sample was sent to the Quest Diagnostics lab and showed the presence of the two benzo-class drugs. The Nevada commission received those results on February 3.
Silva was notified via a letter from the Nevada commission dated February 12.
Silva previously tested positive for drostanolone metabolites and androstane during a January 9 out-of-competition test prior to his UFC 183 win over Nick Diaz. He was tested again on January 19, and he passed.
The UFC has scheduled a 10 a.m. PT press conference on Wednesday morning to address the recent spate of drug test failures, which include Silva, Diaz and Hector Lombard.
Silva was scheduled to appear, either in person or via telephone, in front of the Nevada commission on Monday afternoon. Bleacher Report is in attendance at the meeting and will update this story with more details as they become available.
Jeremy Botter covers mixed martial arts for Bleacher Report. Follow him on Twitter.
Read more MMA news on BleacherReport.com